论文部分内容阅读
目的:观察沙利度胺联合化疗治疗多发性骨髓瘤(MM)的疗效和安全性。方法:选取25例初治或复治MM病人,采用沙利度胺联合VAD、VTD等方案治疗。结果:25例MM中完全缓解(CR)8例,CR率为32%,部分缓解(PR)13例,PR率为52%,进步(I)2例,占8%,总有效率为92%。不良反应主要有乏力、便秘、恶心、嗜睡、腹胀、皮疹、水肿、周围神经病变,均未见明显骨髓抑制。结论:沙利度胺联合VAD、VTD等方案治疗MM是安全有效的。
Objective: To observe the efficacy and safety of thalidomide combined with chemotherapy for multiple myeloma (MM). Methods: Twenty-five newly diagnosed or retreated MM patients were selected and treated with thalidomide combined with VAD and VTD. Results: Among 25 MM patients, 8 cases achieved complete remission (CR), CR rate was 32%, PR was 13, PR rate was 52%, progression (I) was 2, accounting for 8% and total effective rate was 92 %. Adverse reactions are mainly fatigue, constipation, nausea, drowsiness, bloating, rash, edema, peripheral neuropathy, no significant myelosuppression. Conclusion: Thalidomide combined with VAD, VTD and other programs for the treatment of MM is safe and effective.